family with sequence similarity 192 member B, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM192BP profile across patient tissues and cancer cell-line models. FAM192BP expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FAM192BP is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, FAM192BP RNA expression shows 14,260 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, COAD, and UVM as cancer lineages where FAM192BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM192BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM192BP survival associations across molecular data types. FAM192BP RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM192BP RNA expression–survival associations across cancer types. High FAM192BP expression shows unfavorable associations in LIHC, LUSC, KIRP and ACC, but favorable associations in BLCA and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for FAM192BP RNA expression.
This table summarizes FAM192BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM192BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM192BP shows higher tumor expression in COAD, BLCA, HNSC, LUAD, CHOL and LUSC. The COAD box plot shows higher FAM192BP RNA expression in tumor versus normal tissue (log2 FC = +0.530, t-test p < 0.001).
This table shows molecular features associated with FAM192BP in patient tissues and cancer cell lines. In patient samples, FAM192BP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
